BioSpace News Archive

Mercaptor Discoveries (Mercaptor) today advanced their therapeutic candidate to treat brain-inflammation found in patients with long COVID, also known as post-acute sequelae of COVID-19

Medolife Rx, Inc. (“Medolife”), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer products, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that the Company has received a response from the U.S. Food and Drug Administration (FDA) relating to its Pre-Investigational New Drug (Pre-IND) filing on its lead drug candidate Escozine® for the treatment of the SARS-CoV-2 (COVID-19) virus

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical development company, announced the pricing of an underwritten public offering of 3,155,000 shares of common stock at a public offering price of $31.70 per share.

Pear Therapeutics and Serve You Rx Announce Formulary Coverage for Prescription Digital Therapeutic Somryst ® and People with Chronic Insomnia

SpineCraft, LLC and WishBone Medical, Inc. announced a long-term distribution agreement pursuant to which WishBone will distribute SpineCraft’s ASTRA Spine Deformity System in several U.S. markets—with focus on the pediatric spine deformity segment.

Children’s Cancer Research Fund announced the support of OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma and other deadly cancers in kids and adults.

Kite announced that Fosun Kite Biotechnology Co., Ltd., has received approval from the China National Medical Products Administration for axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced a multi-year collaboration with Mila, the Quebec Artificial Intelligence Institute, to accelerate Recursion’s machine learning capabilities.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, Kedrion S.p.A (“Kedrion”) has exercised its option to acquire the remainder of the Company’s plasma-derived business under the terms of the Share Purchase Agreement entered into by the Company and Kedrion.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients.